| All Patients | Patients Followed Over Three Or More Years | Patients Followed Less Than Three Years | |
---|---|---|---|---|
(n = 1693) | (n = 752) | (n = 941) | ||
Gender, n (%) | Female | 1262 (75%) | 579 (77%) | 683 (73%) |
Male | 412 (24%) | 165 (22%) | 247 (26%) | |
Missing | 19 (1%) | 8 (1%) | 11 (1%) | |
Ethnicity, n (%) | Caucasian | 1134 (67%) | 540 (72%) | 594 (63%) |
Black African/Caribbean | 209 (12%) | 100 (13%) | 109 (11%) | |
Asian/other background | 128 (8%) | 52 (7%) | 76 (8%) | |
Not Stated | 79 (5%) | 27 (4%) | 52 (6%) | |
Missing | 143 (8%) | 33 (4%) | 110 (12%) | |
Age (years) | Â | 55 (16) | 55 (15) | 55 (14.7) |
Disease Duration (years) | Â | 11 (10) | 10 (10) | 10 (9.7) |
Tender Joint Counts (28 joints) | Â | 5.0 (6.6) | 4.8 (6.0) | 5.2 (6.5) |
Swollen joint Counts (28 joints) | Â | 2.9 (4.7) | 3.2 (3.9) | 3.3 (4.3) |
Erythrocyte Sedimentation Rate (mm/hr) | Â | 22 (21) | 22 (21) | 21.5 (22) |
Patient Global Assessment (mm) | Â | 46 (28) | 44 (27) | 45 (28) |
DAS28 | Â | 3.83 (1.63) | 3.79 (1.50) | 3.85 (1.62) |
Health Assessment Questionnaire | Â | 1.18 (0.83) | 1.22 (0.86) | 1.18 (0.83) |
EQ5D-3 L |  | 0.53 (0.34) | 0.52 (0.33) | 0.53 (0.34) |